Novo Nordisk a/s. NYSE: NVO He announced that his GLP-1 drugs in chronic obesity, with Ozempic and Wegovy brands, are no longer in deficiency. This led to the fact that the United States Products and Medications Office took half -Glutid, an active ingredient in both, from a list of drug lack of drugs on February … Read more
The shares had another week, despite the February report on workplaces, which became easier than expected. The details of the report were generally optimistic, and government jobs received the biggest blow, as expected. This is just another magazine in the fire of uncertainty that sets fire to reserves, and there is no immediate catalyst to … Read more
Since the US stock market stumbled upon March 2025, the mood quickly switched from a soft planting to wakefulness for exposure. Tit-tit-tit-tit-tie-thawed with tariff threats and rhetoric, the brakes broke the brakes on the trust of investors, while the muddy economic signals of Stoke Resessionary Tread. Add to this air, hissing from high -ranking growths, … Read more